Kangzhe Pharmaceuticals (00867): Class 1 New Drug MG-K10 Humanized Monoclonal Antibody Injection has been newly approved for Chronic Idiopathic Urticaria indication in Phase III Clinical Trial Approval Notification.

Intelligence Finance APP News, Kangde Pharmaceutical (00867) announced that its subsidiary, Demai Pharmaceutical Co., Ltd. (Demai Pharmaceutical), a innovative pharmaceutical company focusing on skin health, is applying for an independent listing on the main board of the Hong Kong Stock Exchange. Together with its affiliated companies, they have the joint development rights (excluding atopic dermatitis (AD)) and exclusive commercialization rights for a new class 1 drug, anti-IL-4R MG-K10 humanized monoclonal antibody injection (MG-K10), which received a drug clinical trial approval notice from the China National Medical Products Administration (NMPA) on September 28, 2025. NMPA has agreed to conduct a phase III clinical trial of MG-K10 for chronic spontaneous urticaria (CSU).